health news today obesity drugs glp-1 past 3 days GLP-1 and eating disorders are not well understood yet : NPR Medicare GLP-1 access raises questions – GLP-1 drug coverage for obesity

Foundayo has improved blood pressure, cholesterol, triglycerides, and other risk markers in studies, but it has not yet been proven to reduce major cardiovascular events

45 In vivo administration of GSH has been demonstrated to enhance the activation of cytotoxic T-cells, but depletion of GSH intracellularly inhibited the activation of lymphocytes, increased susceptibilities of human lymphoid cells to radiation, and suppressed cell-mediated cytotoxic functions, suggesting that intracellular GSH can modulate the function of immune cells

Dark amber vials protect light-sensitive peptides from degradation

A 2021 review and meta-analysis on the effects of betaine on cardiovascular markers describes a lower dose as under 4g per day, and the examined trials used daily doses ranging from 1.5g all the way up to 20g.40 Coenzyme Q10 (60mg) Coenzyme Q10 (more commonly known as CoQ10) is an antioxidant that helps the body convert food into energy and fight against free radicals.41 Too many free radicals and not enough antioxidants in the body can lead to oxidative stress, which may play a role in chronic conditions like cancer, cardiovascular disease, kidney disease, Alzheimers disease, and more.15 Though most studies use higher doses of CoQ10 (100-200mg), a dose of 60mg has shown some success in research.42 An older 2006 study, for example, found that 60mg led to a significant improvement in functional status, symptoms, and quality of life in heart transplant candidates.43 And a more recent 2024 trial found that 300mg CoQ10 phytosome equivalent to 60mg CoQ10 significantly enhanced the physical performance of older adults with statin-associated asthenia (generalized weakness).44 Its worth mentioning that, even though the doses of betaine and CoQ10 are on the lower end, the liposomal delivery method may improve their bioavailability